NDA 050781 · Orapharma
Arestin
Minocycline Hydrochloride · Dental
Last checked: Nov 19, 2026Latest source record: May 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Feb 16, 2001
Approved uses
1
Original approval plus efficacy supplements
Registered trials
291
55 Phase 3, 18 recruiting
FAERS reports
5,103
4,179 serious, 1,656 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 31, 2024.
INDICATIONS AND USE ARESTIN is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.
Mechanism: Mechanism of Action The mechanism of action of ARESTIN as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ARESTIN · MINOCYCLINE HYDROCHLORIDE EQ 1MG BASE · POWDER, EXTENDED RELEASE, DENTAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Minocycline" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic StrokePivotal-lookingCompleted
Beijing Tiantan HospitalAcademic, hospital or other
NCT05836740 · 1,724 participants · Start May 19, 2023 · Primary completion May 20, 2024
Drug: Minocycline hydrochloride capsule; Placebo capsules of Minocycline hydrochloride capsules · For: Ischemic Stroke, Acute
Sites: Beijing, China; Chongqing, China; Shenzhen, China · 58 sites in all
- A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne VulgarisPivotal-lookingCompleted
Vyne Therapeutics Inc.Industry
NCT03271021 · 1,488 participants · Start Jul 17, 2017 · Primary completion Sep 4, 2018
Drug: FMX101; Vehicle Foam · For: Acne Vulgaris
Sites: Phoenix, Arizona; Tucson, Arizona; Bryant, Arkansas · 98 sites in all
- Efficacy and Safety of Minocycline in the Treatment of Intracerebral HemorrhagePivotal-lookingNot yet recruiting
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT07305896 · 1,248 participants (planned) · Start Dec 31, 2025 · Primary completion Dec 31, 2028
Drug: Minocycline · For: Intracerebral Hemorrhage
- Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral HemorrhagePivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07338175 · 1,192 participants (planned) · Start Apr 2, 2026 · Primary completion Jun 2028
Drug: Minocycline hydrochloride capsules; Placebo capsules of Minocycline hydrochloride capsules · For: Intracerebral Hemorrhage
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 41 sites in all
- Minocycline in Stroke Study at MaimonidesPivotal-lookingRecruiting
Joyce ChenAcademic, hospital or other
NCT07237048 · 1,164 participants (planned) · Start Feb 2, 2026 · Primary completion Dec 1, 2028
Drug: Minocycline 200mg · For: Stroke; Ischemia Stroke; Hemorrhagic Strokes and 4 more
Sites: Brooklyn, New York
- Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous ThrombolysisPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07526987 · 934 participants (planned) · Start Jun 5, 2026 · Primary completion Dec 31, 2028
Drug: Minocycline Hydrochloride Capsule (50 mg per capsule); Placebo of Minocycline Hydrochloride Capsule (50 mg per capsule, containing 0 mg of minocycline) · For: Ischaemic Stroke
Sites: Liaocheng, China; Beijing, China · 3 sites in all
- Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)Pivotal-lookingRecruiting
Xiang LuoAcademic, hospital or other
NCT07594314 · 860 participants (planned) · Start May 21, 2026 · Primary completion Dec 2028
Drug: Minocycline hydrochloride capsule; Placebo capsules of Minocycline hydrochloride capsules · For: Acute Ischemic Stroke; Vessel Occlusion; Endovascular Thrombectomy and 2 more
Sites: Wuhan, China
- Efficacy and Safety of Minocycline Add-on in Patients With NeurosyphilisPivotal-lookingNot yet recruiting
Beijing Ditan HospitalAcademic, hospital or other
NCT07904533 · 778 participants (planned) · Start Nov 15, 2026 · Primary completion May 22, 2028
Drug: Minocycline; Minocycline placebo and 1 more · For: Neurosyphilis
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,272
- off label use1,161
- drug intolerance966
- pain929
- rheumatoid arthritis895
- rash793
- nausea791
- arthralgia775
- drug hypersensitivity753
- joint swelling733
- fatigue699
- c-reactive protein increased680
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 38 |
| 2006 | 44 |
| 2007 | 99 |
| 2008 | 73 |
| 2009 | 57 |
| 2010 | 43 |
| 2011 | 55 |
| 2012 | 101 |
| 2013 | 45 |
| 2014 | 151 |
| 2015 | 137 |
| 2016 | 202 |
| 2017 | 230 |
| 2018 | 250 |
| 2019 | 303 |
| 2020 | 300 |
| 2021 | 256 |
| 2022 | 404 |
| 2023 | 422 |
| 2024 | 714 |
| 2025 | 802 |
| 2026 | 345 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Arestin (Minocycline HCl Microspheres)
2024 spending
$5.1M
Beneficiaries
1,027
1,166 claims
Per beneficiary
$4,999
$102.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,870,758 |
| 2021 | $5,500,961 |
| 2022 | $5,467,459 |
| 2023 | $5,814,308 |
| 2024 | $5,134,006 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Minocycline.
Allen JC · Ann Intern Med 1976 · Clinical Trial, Comparative Study
- Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials.
Saelens J, Gramser A, Watzal V, et al. · Neuropsychopharmacology 2025 · Systematic Review, Network Meta-Analysis
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.
Guan L, Beig M, Wang L, et al. · Ann Clin Microbiol Antimicrob 2024 · Systematic Review, Meta-Analysis
- Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.
Lu Y, Guan L, Wu J, et al. · Lancet 2026 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. · Br J Dermatol 2019 · Systematic Review
Sponsor: Orapharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.